Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2020-01-14 Board/Management Inform…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is a press release announcing a significant executive appointment: Steven Hildemann as Executive Vice President, Chief Medical Officer, effective March 1, 2020. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2020-01-14 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information regarding the total number of voting rights and total number of shares of the Company" and explicitly references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and voting rights as of a specific date (December 31, 2019). This content relates to the official disclosure of share capital structure and voting power, which is a regulatory requirement. This type of periodic disclosure regarding share capital and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure. Given the options, it is a specific regulatory announcement. Since there is no specific code for 'Total Voting Rights Disclosure', the closest fit among the provided options that covers specific regulatory disclosures not covered elsewhere is 'Regulatory Filings' (RNS), or potentially a highly specific capital/share related announcement. However, 'Total number of shares' and 'voting rights' are often disclosed under general regulatory filings or specific capital change notices. Since it is a monthly update on the total number of shares and voting rights, it is a mandatory regulatory disclosure. RNS is the general fallback for regulatory announcements. If we consider the closest fit related to share structure changes, 'SHA' (Share Issue/Capital Change) might be considered, but this is a periodic disclosure of the *current* total, not an announcement of a *change* or *issue*. Therefore, RNS (Regulatory Filings) is the most appropriate general category for this mandatory, periodic regulatory disclosure.
2020-01-09 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers, the French financial market regulator) and provides a table detailing the total number of shares and voting rights as of December 31, 2019. This content directly relates to changes in the total share capital and voting rights structure, which aligns best with the 'Share Issue/Capital Change' category (SHA). Although it is a monthly update, the core subject matter is capital structure disclosure.
2020-01-09 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces regulatory news: the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) granted a license update for Dysport® for treating upper limb spasticity in children with cerebral palsy. This is a specific, time-sensitive announcement regarding a product approval/update, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). It is a specific type of corporate communication. Since it is a press release announcing a regulatory/product development milestone, it fits best under the general 'Regulatory Filings' (RNS) category, as it is not covered by the more specific categories like DIV, CAP, or MANG. Given the nature of the announcement (regulatory approval update), RNS is the most appropriate general regulatory category.
2020-01-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a regulatory approval extension for the product Dysport® by the MHRA (Medicines and Healthcare Products Regulatory Agency) in the UK for treating spasticity in children with cerebral palsy. It details the clinical study (Phase III) that supported this approval and provides background information on the condition and the product. This type of announcement, detailing a significant regulatory event or clinical data release, is typically classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific regulatory/product update announcement, it fits best under the general category for significant corporate news that isn't a formal financial report or a transcript. Given the options, it is a major corporate announcement regarding product status and clinical data. It is not a full 10-K, an IR, a CT, or a DEF 14A. It is a press release announcing a regulatory milestone. While it contains detailed information, its format is that of a press release announcing news, not a comprehensive financial report (like 10-K or IR). Since it is a formal announcement of a regulatory/product development milestone, and not a general regulatory filing fallback (RNS), the closest fit for a major, non-financial-period-specific announcement detailing clinical/regulatory progress is often grouped with Earnings Releases (ER) as a primary news release, or sometimes falls under RNS if no better fit exists. However, ER is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Given the nature of the announcement (regulatory approval extension based on clinical data), and lacking a specific 'Regulatory Approval Announcement' code, the most appropriate general category for a major, non-financial-period-specific corporate announcement that is not a transcript or a formal report is often RNS (Regulatory Filings - general regulatory announcements and fallback category). However, if we interpret 'ER' broadly as 'Key Corporate News Release', it might fit, but the definition is strict. Since this is a press release announcing a specific regulatory action and supporting data, and it is not a formal report itself, RNS is the safest fallback for a significant, non-standard filing. Let's re-evaluate: It is a press release announcing a regulatory event. This is a core piece of corporate news. If it were an earnings release, it would be ER. Since it is not, RNS is the fallback. I will classify it as RNS as it is a regulatory announcement that doesn't fit the other specific categories like DIV, CAP, or MANG.
2020-01-06 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and its primary content is the announcement of the company's "corporate agenda for 2020," which lists future dates for sales/results releases, dividend payments, and the Annual Shareholders' Meeting. This type of forward-looking schedule announcement, especially when presented as a press release detailing future reporting events rather than the reports themselves, fits best under the general category of regulatory or corporate announcements. Since it is not a specific report (like 10-K, ER, or IR), nor a management change (MANG) or dividend notice (DIV), and it is a formal announcement of future corporate events, it aligns most closely with a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a specific report. Given it's a calendar of future events, RNS serves as the most appropriate general regulatory announcement category.
2019-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.